Table 1.

Clinical characteristics of breast cancer patients from Latin America were included in the meta-analysis.

Country	Molecular Subtype/Histology	N	Age Years (Median, Range)	Clinical Stage	Reference
Precama Study (Chile, Brazil, Mexico)	HR+ HER2+ TNBC	126	20–45	EBC	[9]
Brazil	HR+ HER2+ TNBC	32	61	EBC	[10]
Brazil	HR+ HER2+ TNBC	86	55	EBC (n = 37) Metastatic (n = 49)	[11]
Brazil	N/A	45	N/A	N/A	[12]
Brazil	HR+ TNBC	294	<50, 100 >50, 142	EBC (n = 269) Metastatic (n = 21)	[13]
Brazil	HR+ TNBC	64	53	EBC	[14]
Peru	HR+ HER2+ TNBC	134	<50, 70 ≥50, 60	EBC	[15]
Mexico	TNBC	29	51	EBC	[16]
Brazil	HR+ TNBC	58	59	EBC	[17]
Brazil	Medullar	40	N/A	EBC	[18]